ストックスクリーナーアプリを入手
24.08
2.03%
-0.4989
アフターアワーズ：
24.13
0.0486
+0.20%
Dice Therapeutics Inc (DICE) 最新ニュース
Talawar Therapeutics Appoints Industry Veterans Mittie Doyle, MD, and Susannah Gray to Board of Directors - PR Newswire
InventHelp Inventor Develops New Card and Dice Combination Game (CHK-6005) - Yahoo Finance
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - The Globe and Mail
Tema Launches Trading & Prediction Markets ETF (DICE) - Yahoo Finance
DICE Therapeutics Inc. (DICE) Peer Comparison – Compare with Others - Value Research
DICE Therapeutics Inc. (DICE) Key Financial Ratios – Valuation, Profitability & More - Value Research
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors - The Manila Times
Autoimmune Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook - openPR.com
DHI Group (DHX) Stock Sees Fair Value Lift As Analysts Weigh ClearanceJobs And Dice - Yahoo Finance
Segment Overview and Major Growth Areas in the Urokinase Market - openPR.com
DHI Group Inc (DHX) (Q2 2026) Earnings Call Highlights: ClearanceJobs Surges 24% While DICE ... - Yahoo Finance
CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors - PR Newswire
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology - Eli Lilly and Company
MindWare Brings a New Reiner Knizia Game and a Giant Dice Tower to Gen Con 2026 - Yahoo Finance
A 'Made in the USA' Monopoly edition cost twice as much to build — and no US factory could even make the dice - Yahoo Finance
An InventHelp 123Invent Client Develops New Money Themed Dice Game (LBT-9813) - Yahoo Finance
The EU rolls dice by setting unambiguous parameters for Satcos operating in 2GHz - Yahoo Finance
Tech Professionals Find Relevant Roles Faster with Dice’s LLM Connector - Yahoo Finance
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188% - The Motley Fool
Morningstar Sees SpaceX Worth Half Its IPO Price - thedeepdive.ca
OpenAI Files Confidential S-1 With SEC, Targeting IPO as Soon as Q4 - thedeepdive.ca
SpaceX Cuts IPO Valuation Target to $1.8 Trillion After Investor Feedback - TheDeepDive.ca
TWO DICE SECURES STRATEGIC INVESTMENT FROM OAK VIEW GROUP - Yahoo Finance
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire
Russia is about to roll the dice on crypto regulation. Here’s its playbook - Yahoo Finance
Jim Cramer on JetBlue Airways: “It’s a Dice Roll, and I Don’t Like Dice Rolls” - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More - 24/7 Wall St.
EA Slashes Battlefield Headcount In a Pivot to AI - Yahoo Finance
Burnout, layoffs, 'ghost jobs' in Dice's 2026 tech survey - Stock Titan
Muted and missing M&As: JPM deals absent in 2026 - BioWorld News
Baron of Dice Answers the Questions Players Keep Asking - Yahoo Finance
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
Boyd Gaming reveals $160M revamp for Par-A-Dice Casino - Yahoo Finance
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes - American Heart Association Journals
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
Don't Buy Summit Therapeutics Until This Big Thing Happen - The Motley Fool
Here Are Wednesday's Top Wall Street Analyst Research Calls: DHL Group, NetApp, Nutanix, Oracle, Snowflake, Urban Outfitters, Zscaler and More - 247wallst.com
Big pharma drives surge in biopharma job cuts in 2025 - BioWorld News
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy - Business Wire
Updated: DICE rolls on as lead oral IL-17 candidate meets proof-of-concept in PhI trial, sending shares higher - Endpoints News
EA May Sell BioWare And DICE Or Close Other Studios, Says Analyst - Yahoo Finance
RNA Therapeutics Market Size to Reach USD 26.13 Billion by 2034 - BioSpace
Interleukin-17 Inhibitors Market to Witness Strong Growth During the Forecast Period (2020-2034) Driven by Expanding Indications and Therapeutic Innovation | DelveInsight - PR Newswire
Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant - Fierce Pharma
Fever Acquires Ticketing Platform Dice - Yahoo Finance
Forward Therapeutics, the first biotech from Curie.Bio, raises $50M for oral small molecules in immunology - Endpoints News
DHI Group Inc (DHX) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Focus - Yahoo Finance
Dice Therapeutics Stock Price, News & Analysis - Stock Titan
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld News
10 Best Low Volatility Stocks to Buy Now - Insider Monkey
The top 10 pharma R&D budgets for 2024 - Fierce Biotech
Satya Nadella Says AI Agents Will Replace 'Knowledge Work'—But There's One Role Humans Will Always Need To Play - Yahoo Finance
Sage lawsuit enforces standstill as board evaluates Biogen offer - BioWorld News
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
Gambling.com Rolls The Dice On OddsJam's Parent; $80M Upfront Consideration For Instant Revenue Boost - Yahoo Finance
Combos, New MOAs, And Oral Formulations Of Injectables: Lilly’s Immunology Strategy - insights.citeline.com
Why Did Eli Lilly Stock Fall 6%? - Trefis
Mounjaro To Lead Eli Lilly’s Q3 Growth - Trefis
Lilly’s Ebglyss enters US atopic dermatitis market with FDA nod - BioWorld News
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies - Business Wire
AbbVie acquires Cerevel Therapeutics for $45 per share - TechTarget
Avalo Therapeutics Appoints Dr. Mittie Doyle as Chief Medical Officer - citybiz
DICE Therapeutics (NASDAQ: DICE)Share Price - intelligentinvestor.com.au
EX-99.1 - SEC.gov
Lilly to buy Morphic in $3B bet on inflammation drug - BioPharma Dive
Periodontal Therapeutics Market Size Report, 2024-2030 - Grand View Research
Arlington's Sands Capital raises hefty sum for third life sciences fund - The Business Journals
Life Sciences Group Of The Year: Fenwick - law360.com
Changing Faces: Pharma and biotech hires from January 2024 - pharmaphorum
Perpetual aims to be peptide powerhouse - BioWorld News
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):